NCT02571049已完成2 期
Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The Percentage of Subjects Reporting Pain Freedom at 60 Minutes Post-treatment
研究概览
简要总结
Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
详细描述
Pilot study to compare the proportion of subjects experiencing pain freedom at 60 minutes post-treatment between headache treated with Strength A of DFN-11 and Strength B of DFN-11
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of episodic migraine, with or without aura for at least 1 year prior to screening
- •Experience an average of 2 to 8 migraines per month for the past 12 months of which approximately 75% or more rapidly escalate to moderate or severe pain within 2 hours of onset
- •Females must:
- •be practicing an effective method of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
- •be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
- •be postmenopausal (spontaneous amenorrhea for at least 1 year)
- •Females of child-bearing potential must have a negative urine pregnancy test at screening
- •Able and willing to read and comprehend written instructions and complete the electronic diary information required by the protocol
- •Must have internet access to complete daily headache diary
排除标准
- •Inability to distinguish migraine from other primary headaches
- •Experiences headache of any kind at a frequency greater than or equal to 15 days per month
- •Chronic opioid therapy (> 10 days in the 30 days prior to screening)
- •Current treatment with monoamine oxidase A (MAO-A) inhibitors or use within 4 weeks before randomization
- •Hemiplegic or basilar migraine
- •History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
- •Uncontrolled hypertension (screening systolic/diastolic blood pressure > 140/90 mmHg in 2 out of 3 readings)
- •History of epilepsy or conditions associated, which in the opinion of the Investigator, increase the likelihood of present day seizure
- •History (within 2 years) of drug or alcohol abuse as defined by DSM-IV-TR criteria.
- •Systemic disease, which in the opinion of the Investigator, would contraindicate participation
- •History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation
- •Pregnant or lactating women
- •Have taken any investigational medication within 30 days before randomization, or are scheduled to receive an investigational drug
- •Subjects with a positive urine drug screen for recreational drugs or marijuana (whether legal or not) or for prescription drugs not explained by stated concomitant medications
- •Clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.
- •Fridericia's corrected QT (QTcF) interval greater than 450 msec
- •Severe renal impairment (creatinine > 2 mg/dl)
- •Serum total bilirubin > 2.0 mg/dL
- •Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal
- •Subjects who in the opinion of the investigator experience rebound headache from caffeine usage
研究组 & 干预措施
Sumatriptan 3 mg then 6 mg
Experimental
DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
干预措施: DFN-11 (Drug)
Sumatriptan 6 mg then 3 mg
Experimental
Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
干预措施: DFN-11 (Drug)
结局指标
主要结局
The Percentage of Subjects Reporting Pain Freedom at 60 Minutes Post-treatment
时间窗: 60 minutes post-treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Pilot Study of DFN-11 Injection in Medication Overuse HeadacheMedication Overuse HeadacheNCT02583425Dr. Reddy's Laboratories Limited27
已完成
3 期
CKD-11101 Phase 3 SC StudyAnemia of Chronic Kidney DiseaseNCT03431623Chong Kun Dang Pharmaceutical248
已完成
2 期
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome PatientsPrimary Sjögren's SyndromeNCT04605978Institut de Recherches Internationales Servier48
已完成
3 期
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental FatModerate to Severe Convexity of Submental FatSafetyEfficacyNCT02035267Kythera Biopharmaceuticals93
已完成
3 期
Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of AgeModerate to Severe Convexity of Submental FatSafetyEfficacyNCT02123134Kythera Biopharmaceuticals55